世界のホルモン不応性前立腺がん（HRPCA）市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Hormone Refractory Prostate Cancer (HRPCA) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-2104Z07177 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品

• 販売価格（消費税別）

Single User	￥504,600 (USD3,480)	▷ お問い合わせ
Multi User	￥756,900 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,009,200 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、ホルモン不応性前立腺がん（HRPCA）のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ホルモン不応性前立腺がん（HRPCA）の種類別市場規模（細胞毒性剤、抗アンドロゲン、ワクチン、放射性医薬品）、用途別市場規模（病院、外来手術センター、専門診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ホルモン不応性前立腺がん（HRPCA）の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Astellas Inc、Sanofi S.A、Dendreon Corporation, Bayer AG、Johnson & Johnson ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：細胞毒性剤、抗アンドロゲン、ワクチン、放射性医薬品 ・用途別分析2016年-2026年：病院、外来手術センター、専門診療所、その他 ・ホルモン不応性前立腺がん（HRPCA）の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ホルモン不応性前立腺がん（HRPCA）のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ホルモン不応性前立腺がん（HRPCA）のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ホルモン不応性前立腺がん（HRPCA）の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ホルモン不応性前立腺がん（HRPCA）の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Hormone Refractory Prostate Cancer (HRPCA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Hormone Refractory Prostate Cancer (HRPCA) size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Hormone Refractory Prostate Cancer (HRPCA) market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Hormone Refractory Prostate Cancer (HRPCA) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals

Market segment by Application, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others

Market segment by players, this report covers
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Hormone Refractory Prostate Cancer (HRPCA)
1.2 Classification of Hormone Refractory Prostate Cancer (HRPCA) by Type
1.2.1 Overview: Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type in 2020
1.2.3 Cytotoxic Agents
1.2.4 Anti-Androgens
1.2.5 Vaccines
1.2.6 Radio-Pharmaceuticals
1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market by Application
1.3.1 Overview: Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size & Forecast
1.5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Region
1.5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region, (2016-2021)
1.5.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2016-2026)
1.5.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2016-2026)
1.5.6 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
1.6.2 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
1.6.3 Hormone Refractory Prostate Cancer (HRPCA) Trends Analysis
2 Company Profiles
2.1 Astellas Inc
2.1.1 Astellas Inc Details
2.1.2 Astellas Inc Major Business
2.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
2.1.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Astellas Inc Recent Developments and Future Plans
2.2 Sanofi S.A
2.2.1 Sanofi S.A Details
2.2.2 Sanofi S.A Major Business
2.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
2.2.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Sanofi S.A Recent Developments and Future Plans
2.3 Dendreon Corporation, Bayer AG
2.3.1 Dendreon Corporation, Bayer AG Details
2.3.2 Dendreon Corporation, Bayer AG Major Business
2.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
2.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Dendreon Corporation, Bayer AG Recent Developments and Future Plans
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business
2.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
2.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Johnson & Johnson Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share
3.2.2 Top 10 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share
3.2.3 Market Competition Trend
3.3 Hormone Refractory Prostate Cancer (HRPCA) Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Type (2016-2021)
4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2016-2021)
5.2 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2026)
6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2026)
6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
6.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2026)
6.3.2 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
6.3.3 Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
6.3.4 Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2026)
7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2026)
7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
7.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2026)
7.3.2 Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
7.3.3 France Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
7.3.5 Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
7.3.6 Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2026)
8.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2026)
8.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region
8.3.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2016-2026)
8.3.2 China Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
8.3.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
8.3.4 South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
8.3.5 India Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
8.3.7 Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2026)
9.2 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2026)
9.3 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
9.3.1 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2026)
9.3.2 Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
9.3.3 Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2026)
10.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2026)
10.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
10.3.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2026)
10.3.2 Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
10.3.4 UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Hormone Refractory Prostate Cancer (HRPCA) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Region (2016-2021)
Table 5. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region (2021-2026)
Table 6. Astellas Inc Corporate Information, Head Office, and Major Competitors
Table 7. Astellas Inc Major Business
Table 8. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 9. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Sanofi S.A Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi S.A Major Business
Table 12. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 13. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Dendreon Corporation, Bayer AG Corporate Information, Head Office, and Major Competitors
Table 15. Dendreon Corporation, Bayer AG Major Business
Table 16. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 17. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 19. Johnson & Johnson Major Business
Table 20. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 21. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Players (2019-2021)
Table 23. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players (2019-2021)
Table 24. Breakdown of Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 25. Hormone Refractory Prostate Cancer (HRPCA) Players Head Office, Products and Services Provided
Table 26. Hormone Refractory Prostate Cancer (HRPCA) Mergers & Acquisitions in the Past Five Years
Table 27. Hormone Refractory Prostate Cancer (HRPCA) New Entrants and Expansion Plans
Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Type (2016-2021)
Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2016-2021)
Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Type (2021-2026)
Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2021)
Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Application (2021-2026)
Table 33. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2021) & (USD Million)
Table 34. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (USD Million)
Table 35. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2021) & (USD Million)
Table 36. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (USD Million)
Table 37. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2021) & (USD Million)
Table 38. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (USD Million)
Table 39. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2021) & (USD Million)
Table 40. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (USD Million)
Table 41. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2021) & (USD Million)
Table 42. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (USD Million)
Table 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2021) & (USD Million)
Table 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (USD Million)
Table 45. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2021) & (USD Million)
Table 46. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (USD Million)
Table 47. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2021) & (USD Million)
Table 48. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (USD Million)
Table 49. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2016-2021) & (USD Million)
Table 50. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Region (2021-2026) & (USD Million)
Table 51. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2021) & (USD Million)
Table 52. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (USD Million)
Table 53. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2021) & (USD Million)
Table 54. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (USD Million)
Table 55. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2021) & (USD Million)
Table 56. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (USD Million)
Table 57. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2016-2021) & (USD Million)
Table 58. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2021-2026) & (USD Million)
Table 59. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2016-2021) & (USD Million)
Table 60. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2021-2026) & (USD Million)
Table 61. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2016-2021) & (USD Million)
Table 62. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Picture
Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type in 2020
Figure 3. Cytotoxic Agents
Figure 4. Anti-Androgens
Figure 5. Vaccines
Figure 6. Radio-Pharmaceuticals
Figure 7. Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application in 2020
Figure 8. Hospitals Picture
Figure 9. Ambulatory Surgical Centers Picture
Figure 10. Specialty Clinics Picture
Figure 11. Others Picture
Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region (2016-2026)
Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region in 2020
Figure 16. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
Figure 21. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
Figure 22. Hormone Refractory Prostate Cancer (HRPCA) Market Trends
Figure 23. Astellas Inc Recent Developments and Future Plans
Figure 24. Sanofi S.A Recent Developments and Future Plans
Figure 25. Dendreon Corporation, Bayer AG Recent Developments and Future Plans
Figure 26. Johnson & Johnson Recent Developments and Future Plans
Figure 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players in 2020
Figure 29. Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 30. Global Top 3 Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share in 2020
Figure 31. Global Top 10 Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share in 2020
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 33. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type in 2020
Figure 34. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2021-2026)
Figure 35. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application in 2020
Figure 36. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2021-2026)
Figure 37. North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2016-2026)
Figure 38. North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2016-2026)
Figure 39. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2016-2026)
Figure 40. United States Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2016-2026)
Figure 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2016-2026)
Figure 45. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2016-2026)
Figure 46. Germany Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. France Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. United Kingdom Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Russia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Italy Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2016-2026)
Figure 52. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2016-2026)
Figure 53. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Region (2016-2026)
Figure 54. China Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South Korea Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. India Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Australia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2016-2026)
Figure 61. South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2016-2026)
Figure 62. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2016-2026)
Figure 63. Brazil Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Argentina Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Type (2016-2026)
Figure 66. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2016-2026)
Figure 67. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Country (2016-2026)
Figure 68. Turkey Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. UAE Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source

---